Diabetes research and clinical practice最新文献

{"title":"Black Death protective gene mutation shows ambiguous role in type 1 diabetes, its complications, and common viral infections","authors":"Bartosz Słomiński ,&nbsp;Julia Gładysz ,&nbsp;Maria Skrzypkowska ,&nbsp;Monika Ryba-Stanisławowska ,&nbsp;Dariusz Nowicki ,&nbsp;Agnieszka Szalewska-Pałasz ,&nbsp;Małgorzata Myśliwiec","doi":"10.1016/j.diabres.2025.112287","DOIUrl":"10.1016/j.diabres.2025.112287","url":null,"abstract":"<div><h3>Aims</h3><div>Because ERAP2 is implicated in infections and autoimmune diseases, we hypothesize that the rs9939609 <em>ERAP2</em> polymorphism, with allele frequencies observed in human samples from both before and after the Black Death, may influence type 1 diabetes (T1D), its complications, and common viral infections.</div></div><div><h3>Methods</h3><div>We examined 400 patients with T1D and 300 healthy, age-matched controls. The analysis focused on the <em>ERAP2</em> polymorphism in relation to T1D complications and comorbidities, the history of common childhood viral infections, and the inflammatory status of T1D patients.</div></div><div><h3>Results</h3><div>The T allele is linked to a decreased risk of developing diabetes, modulates its complications in a differential manner, and has diverse effects on the inflammatory status of T1D patients. Our results also indicate statistically significant differences in the correlation of monocyte subsets, the quantitative status of CD4 + CD25^high FOXP3⁺ regulatory T cells, and susceptibility to common childhood viral infections between different <em>ERAP2</em> variants.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that the rs2549794 <em>ERAP2</em> polymorphism may serve as a genetic marker for susceptibility to T1D complications and comorbidities, further emphasizing the role of ERAP2-mediated pathways in their etiology. These results also provide new evidence supporting the hypothesis of balancing selection at this locus, driven by autoimmune and infectious diseases.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112287"},"PeriodicalIF":6.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic steatosis is associated with impaired hepatic glucose uptake under hyperglycemic conditions, a dynamic whole-body 18F-FDG PET approach","authors":"Jeremy Basset-Sagarminaga ,&nbsp;Tineke van de Weijer ,&nbsp;Evi Koene ,&nbsp;Yvonne M.H. Op den Kamp-Bruls ,&nbsp;Esther Phielix ,&nbsp;Kim Brouwers ,&nbsp;Sam Springer ,&nbsp;Edvin Johansson ,&nbsp;Lars Johansson ,&nbsp;Fotis Kotasidis ,&nbsp;Paul Deak ,&nbsp;Joachim E. Wildberger ,&nbsp;Roel Wierts ,&nbsp;Iina Laitinen ,&nbsp;Patricia Iozzo ,&nbsp;Patrick Schrauwen ,&nbsp;Vera B. Schrauwen-Hinderling","doi":"10.1016/j.diabres.2025.112288","DOIUrl":"10.1016/j.diabres.2025.112288","url":null,"abstract":"<div><h3>Objective</h3><div>Accumulation of fat in the liver is associated with hepatic insulin resistance, as evidenced by a reduced insulin-induced suppression of endogenous glucose production (EGP). However, suppression of EGP has been proposed to be mainly a reflection of indirect insulin action.Hepatic glucose uptake in the postprandial state is another aspect of hepatic insulin sensitivity, which is seldom investigated. Here we sought to examine if hepatic steatosis is associated with a reduced hepatic glucose uptake under conditions of hyperglycemia and hyperinsulinemia.</div></div><div><h3>Methods</h3><div>In this cross-sectional study, 15 participants with a range of liver fat content (0.9–18 %) as assessed by ¹H-MRSwere recruited. Whole-body insulin sensitivity and insulin-induced suppression of EGP were measured by a two-step euglycemic-hyperinsulinemic clamp. A hyperglycemic-hyperinsulinemic clamp was used to measure hepatic and tissue-specific glucose uptake using a dynamic whole-body ¹⁸F-FDG PET protocol.</div></div><div><h3>Results</h3><div>Under conditions of hyperglycemic-hyperinsulinemia, hepatic glucose uptake correlated strongly and inversely with liver fat content (r = -0.756, p &lt; 0.001). Hepatic glucose uptake also correlated with insulin-stimulated EGP suppression (r = 0.616, p = 0.015). Adipose tissue insulin sensitivity was negatively associated with liver fat content and positively with hepatic, skeletal muscle, and adipose tissue glucose uptake.</div></div><div><h3>Conclusion</h3><div>We show that another aspect of hepatic insulin resistance, namely the ability of insulin to stimulate hepatic glucose uptake under hyperglycemic conditions, is negatively associated with hepatic fat content. This suggests that hepatic glucose uptake is another factor that may be important in Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) and the risk for type 2 diabetes, and needs further investigation.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112288"},"PeriodicalIF":6.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes. Part B: Risks of sodium-glucose co-transporter inhibitor use in type 1 diabetes and ketoacidosis risk mitigation strategies.","authors":"Jennifer Ngan, David N O'Neal, Melissa H Lee, Yee Wen Kong, Richard J MacIsaac","doi":"10.1016/j.diabres.2025.112284","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112284","url":null,"abstract":"<p><p>Sodium-glucose co-transporter (SGLT) inhibitors have been evaluated for use in people with type 1 diabetes (T1D). Despite evidence for glycaemic and non-glycaemic benefits in people with T1D as discussed in the accompanying review (Part A), the increased risk of diabetic ketoacidosis (DKA) with this class of medication remains a barrier limiting its widespread use in this population. DKA is a serious and life-threatening complication of diabetes and the excess risk associated with SGLT inhibitor use needs to be addressed before this medication could be considered as part of glycaemia and complications management in people with T1D. Understanding factors that increase DKA risk in the setting of SGLT inhibitors, as well as an appreciation of general DKA risk factors, may facilitate the development of strategies that allow for an acceptable risk versus benefit ratio to permit the use of SGLT inhibitors in people with T1D.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112284"},"PeriodicalIF":6.1,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of different glycemic criteria for the diagnosis of gestational diabetes mellitus: a target trial emulation","authors":"Zhijuan Cao ,&nbsp;Tao Wang ,&nbsp;Xiaoxian Qu ,&nbsp;Jiaqi Dong ,&nbsp;Shengyu Wu ,&nbsp;Yirong Bao ,&nbsp;Jue Li ,&nbsp;Hao Ying","doi":"10.1016/j.diabres.2025.112283","DOIUrl":"10.1016/j.diabres.2025.112283","url":null,"abstract":"<div><h3>Aims</h3><div>There’s no scientific consensus on the best way to diagnose gestational diabetes mellitus (GDM) globally. This study uses target trial emulation to assess different glycemic criteria for GDM diagnosis.</div></div><div><h3>Methods</h3><div>38,995 singleton − pregnant women who took a 75 − g oral glucose tolerance test at 24–32 weeks of gestation were involved. Cloning, censoring, and inverse probability weighting were applied for emulation. Log − binomial regression estimated the effects of various criteria on adverse birth outcomes, and statistical significance and estimates were evaluated.</div></div><div><h3>Results</h3><div>4,539 women (11.6 %) were diagnosed with lower criteria, 2,463 (6.3 %) with intermediate, and 1,744 (4.5 %) with higher criteria. The proportion of large − for − gestational − age (LGA) infants was 7.12 % in the lower criteria group and 8.26 % in the higher criteria group (RR = 0.96, 95 % CI: 0.90 to 1.02). Similar LGA risks were found between intermediate and lower criteria. All outcomes showed statistical significance and agreement with targeted trials.</div></div><div><h3>Conclusions</h3><div>Lower glycemic criteria increased GDM diagnosis 2.53 − fold compared to higher criteria and 1.80 − fold relative to intermediate criteria, yet risks of LGA newborns and other issues remained unchanged.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112283"},"PeriodicalIF":6.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144146884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Time-trends in body mass index, and overweight and obesity as independent risk factors for diabetes angiopathy in young females with type 1 diabetes - A nationwide study in Sweden\" [Diab. Res. Clin. Pract. 204 (2023) 110899].","authors":"Josephine Haas, Mikael Andersson Franko, Anna Lindholm Olinder, Thomas Nyström, Martina Persson","doi":"10.1016/j.diabres.2025.112276","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112276","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112276"},"PeriodicalIF":6.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is diabetic ketoacidosis at diagnosis of type 1 diabetes associated with secondary episodes of ketoacidosis? A nationwide longitudinal study of Swedish children from 2012 to 2019","authors":"Johan H. Wersäll ,&nbsp;Peter Adolfsson ,&nbsp;Jan Ekelund ,&nbsp;Gun Forsander ,&nbsp;Karin Åkesson ,&nbsp;Ragnar Hanas","doi":"10.1016/j.diabres.2025.112282","DOIUrl":"10.1016/j.diabres.2025.112282","url":null,"abstract":"<div><h3>Aims</h3><div>The primary aim was to analyze if diabetic ketoacidosis (DKA) at diagnosis of type 1 diabetes in children is associated with an increased risk of future DKA episodes. Secondary aims were to assess the effects of parental education level and family income on the risk of recurrent DKA.</div></div><div><h3>Methods</h3><div>This was a national, retrospective cohort study of children aged 9 months to &lt; 18 years with type 1 diabetes in Sweden from January 1, 2012, to December 31, 2019. DKA was defined as pH &lt; 7.30. Cox proportional hazards models were used to estimate the risk of DKA with adjustments for sex, age, disposable income and parental education level.</div></div><div><h3>Results</h3><div>A total of 4523 children were included in the study, of whom 909 (20.1 %) had DKA at diagnosis of type 1 diabetes. DKA at diagnosis was not associated with increased risk of another DKA episode during established diabetes (HR 0.77, p = 0.46, 95 %C.I. 0.41–1.51). Low parental education level and low household income were independent predictors of DKA during established diabetes.</div></div><div><h3>Conclusions</h3><div>DKA at diagnosis of type 1 diabetes does not predict further episodes of DKA. Adverse social determinants of health likely predict long-term increased risk of DKA episodes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112282"},"PeriodicalIF":6.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular complications in prediabetes: a systematic review & meta-analysis","authors":"Sama Thiab ,&nbsp;Taim Akhal ,&nbsp;Meriem Akeblersane ,&nbsp;Heet Sheth ,&nbsp;Stephen L. Atkin ,&nbsp;Alexandra E. Butler","doi":"10.1016/j.diabres.2025.112261","DOIUrl":"10.1016/j.diabres.2025.112261","url":null,"abstract":"<div><h3>Aims</h3><div>Prediabetes prevalence is increasing with a risk of developing microvascular complications. The American Diabetes Association (ADA) definition is a hemoglobin A1c(HbA1c) of 5.7 %–6.4 % (39–46 mmol/mol) versus the International Experts Committee (IEC) range of 6.0–6.4 % (42–46 mmol/mol). We aimed to determine whether a prediabetic HbA1c or fasting blood glucose (FBG) cut-off exists, above which individuals exhibit increased microvascular complications.</div></div><div><h3>Methods</h3><div>All prediabetes studies in Embase, MEDLINE, Scopus, Cochrane, CINAHL databases from 1990–May 2023 reporting retinopathy, nephropathy, and/or neuropathy included.</div></div><div><h3>Results</h3><div>21,215 studies identified, 35 analyzed.<!--> <!-->Prevalence and incidence of retinopathy was significantly higher by ADA versus IEC criteria (Weighted Mean Difference 2.37 [2.31,2.43] and 1.32 [1.25,1.40], respectively). Receiver Operator Curves for IEC criteria: sensitivity 65.3% specificity 88.0% for retinopathy, AUC 0.88; for ADA criteria at 5.9%: sensitivity 77.5%, specificity 78.4%, AUC 0.73. No studies reported nephropathy/neuropathy by IEC criteria; nephropathy prevalence 1.0%-15.0% for HbA1c and FBG criteria.</div></div><div><h3>Conclusions</h3><div>Prediabetes ADA criteria (HbA1c 5.7–6.4 %) identified significantly more retinopathy than IEC criteria (HbA1c 6.0–6.4 %), suggesting that ADA criteria are preferable for early retinopathy detection and clinical retinal screening may be considered at HbA1c ≥ 5.7 %. Insufficient studies on the prevalence of nephropathy and neuropathy in prediabetes were available.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112261"},"PeriodicalIF":6.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144139155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Diabetes Federation membership grows to 251 diabetes associations.","authors":"","doi":"10.1016/j.diabres.2025.112281","DOIUrl":"10.1016/j.diabres.2025.112281","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112281"},"PeriodicalIF":6.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the benefits vs risk profile of sodium-glucose co-transporter inhibitor use in type 1 diabetes Part A: Benefits of sodium-glucose co-transporter inhibitor use in type 1 diabetes","authors":"Jennifer Ngan ,&nbsp;David N O’Neal ,&nbsp;Melissa H Lee ,&nbsp;Yee Wen Kong ,&nbsp;Richard J MacIsaac","doi":"10.1016/j.diabres.2025.112278","DOIUrl":"10.1016/j.diabres.2025.112278","url":null,"abstract":"<div><div>There has been increasing research into non-insulin therapies to assist people living with type 1 diabetes (T1D) improve their glucose control and to help prevent the development and progression of vascular and kidney complications. In particular, the sodium-glucose co-transporter (SGLT) inhibitor class of medication has received attention as an adjunctive therapy in T1D. These medications have an established and important role in the management of type 2 diabetes, heart failure and chronic kidney disease. Unfortunately, SGLT inhibitors, especially when taken during periods of fasting or intercurrent illness, can precipitate diabetic ketoacidosis. Considering the above, SGLT inhibitors have failed to obtain an indication for use in the setting of T1D. Here we review the potential glycaemic, cardiovascular and kidney benefits of SGLT inhibitors for people with T1D.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112278"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the comment on: High fasting plasma glucose in early pregnancy and adverse pregnancy outcomes in Chinese women","authors":"Ming Gao ,&nbsp;Ninghua Li ,&nbsp;Hui Wang ,&nbsp;David Simmons ,&nbsp;Xilin Yang","doi":"10.1016/j.diabres.2025.112271","DOIUrl":"10.1016/j.diabres.2025.112271","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"225 ","pages":"Article 112271"},"PeriodicalIF":6.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}